This filing from Alpha Buying outlines an investment strategy focused on tracking strategic investments made by industry giants like NVIDIA and Merck. It highlights specific smaller companies (Coherent, CoreWeave, Alector, Entrada Therapeutics, Eikon Therapeutics) that these larger players have invested in, suggesting potential future growth areas in AI infrastructure and biotech.
Alpha Buying's filing details a unique investment approach: 'following the money' of dominant industry players like NVIDIA and Merck. This strategy identifies smaller companies (Coherent, CoreWeave, Alector, Entrada Therapeutics, Eikon Therapeutics) that have received strategic investments, indicating where these giants see future demand, scarcity, or strategic value. For traders, this provides a 'scouting report' on potential growth areas in AI infrastructure (Coherent, CoreWeave) and biotech (Alector, Entrada, Eikon), suggesting these smaller companies could benefit from the larger companies' expertise, resources, and potential future partnerships or acquisitions. The short-term implication is increased investor interest in these smaller firms, while the long-term opportunity lies in their potential to become durable, profitable businesses, though the filing also cautions about the power imbalance in such relationships.